Raf: A strategic target for therapeutic development against cancer

Journal of Clinical Oncology

Volumn 23, Issue 27, 2005, Pages 6771-6790

  Beeram, Muralidhar ^a   Patnaik, Amita ^a   Rowinsky, Eric K ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANSAMYCIN DERIVATIVE; ANTISENSE OLIGONUCLEOTIDE; B RAF KINASE; C RAF KINASE; CARBOPLATIN; CELL SURFACE RECEPTOR; CGP 69846A; CISPLATIN; DOXORUBICIN; FLUOROURACIL; GEFITINIB; GELDANAMYCIN; GEMCITABINE; IRINOTECAN; ISOPROTEIN; L 779450; MITOGEN ACTIVATED PROTEIN KINASE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PHOSPHOTRANSFERASE INHIBITOR; RADICICOL; RAF KINASE INHIBITOR; RAF PROTEIN; RAS PROTEIN; SORAFENIB; UNCLASSIFIED DRUG; A RAF KINASE; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; ONCOPROTEIN; PYRIDINE DERIVATIVE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACUTE KIDNEY FAILURE; AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANEMIA; CELL NUCLEUS; CELL PROLIFERATION; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; COOMBS POSITIVE HEMOLYTIC ANEMIA; CYTOPLASM; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SELECTIVITY; DRUG TARGETING; DRUG WITHDRAWAL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REGULATION; ENZYME STRUCTURE; FATIGUE; FEVER; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; LYMPHOCYTOPENIA; MALAISE; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MULTIPLE CYCLE TREATMENT; MUTAGENESIS; NEUTROPENIA; NONHUMAN; ONCOGENE; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN STRUCTURE; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL; RASH; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SOLID TUMOR; THROMBOCYTOPENIA; THROMBOPLASTIN TIME; TREATMENT PLANNING; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VOMITING; ANIMAL; COMPARATIVE STUDY; DOWN REGULATION; DRUG DELIVERY SYSTEM; GENETICS; METABOLISM; MOLECULAR BIOLOGY; MUTATION; NEOPLASM; PATHOPHYSIOLOGY; PHYSIOLOGY; SENSITIVITY AND SPECIFICITY;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; DOWN-REGULATION; DRUG DELIVERY SYSTEMS; HUMANS; MAP KINASE KINASE 1; MAP KINASE SIGNALING SYSTEM; MOLECULAR BIOLOGY; MUTATION; NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS A-RAF; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RAF; PYRIDINES; RAF KINASES; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION;

EID: 27244457769     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.08.036     Document Type: Review

References (236)

1. Khosravi-Far R, Der CJ: The Ras signal transduction pathway. Cancer Metastasis Rev 13:67-89, 1994
2. Campbell SL, Khosravi-Far R, Rossman KL, et al: Increasing complexity of Ras signaling. Oncogene 17:1395-1413, 1998
3. Vojtek AB, Der CJ: Increasing complexity of the Ras signaling pathway. J Biol Chem 273: 19925-19928, 1998
4. Chong H, Vikis HG, Guan KL: Mechanisms of regulating the Raf kinase family. Cell Signal 15:463-469, 2003
5. Joneson T, Bar-Sagi D: Ras effectors and their role in mitogenesis and oncogenesis. J Mol Med 75:587-593, 1997
6. Heidecker G, Huleihel M, Cleveland JL, et al: Mutational activation of c-raf-1 and definition of the minimal transforming sequence. Mol Cell Biol 10:2503-2512, 1990
7. Schaap D, van der Wal J, Howe LR, et al: A dominant-negative mutant of raf blocks mitogen-activated protein kinase activation by growth factors and oncogenic p21ras. J Biol Chem 268: 20232-20236, 1993
8. Yuen ST, Davies H, Chan TL, et al: Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res 62:6451-6455, 2002
9. Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417:949-954, 2002
10. Storm SM, Rapp UR: Oncogene activation: C-raf-1 gene mutations in experimental and naturally occurring tumors. Toxicol Lett 67:201-210, 1993
11. Mercer KE, Pritchard CA: Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 1653:25-40, 2003
12. Sommerer F, Vieth M, Markwarth A, et al: Mutations of BRAF and KRAS2 in the development of Barrett's adenocarcinoma. Oncogene 23:554-558, 2004
13. Callans LS, Naama H, Khandelwal M, et al: Raf-1 protein expression in human breast cancer cells. Ann Surg Oncol 2:38-42, 1995
14. Rajagopalan H, Bardelli A, Lengauer C, et al: Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418:934, 2002
15. Nikiforova MN, Kimura ET, Gandhi M, et al: BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88:5399-5404, 2003
16. Kimura ET, Nikiforova MN, Zhu Z, et al: High prevalence of BRAF mutations in thyroid cancer: Genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63:1454-1457, 2003
17. Pollock PM, Meltzer PS: A genome-based strategy uncovers frequent BRAF mutations in melanoma. Cancer Cell 2:5-7, 2002
18. Cohen Y, Xing M, Mambo E, et al: BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 95:625-627, 2003
19. Cohen MS, Hussain HB, Moley JF: Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors. Surgery 132:960-967, 2002
20. Singer G, Oldt R III, Cohen Y, et al: Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 95:484-486, 2003
21. Tannapfel A, Sommerer F, Benicke M, et al: Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 52:706-712, 2003
22. Lee JW, Soung YH, Park WS, et al: BRAF mutations in acute leukemias. Leukemia 18:170-172, 2004
23. Weber A, Langhanki L, Sommerer F, et al: Mutations of the BRAF gene in squamous cell carcinoma of the head and neck. Oncogene 22:4757-4759, 2003
24. Brose MS, Volpe P, Feldman M, et al: BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 62:6997-7000, 2002
25. Lee SH, Lee JW, Soung YH, et al: BRAF and KRAS mutations in stomach cancer. Oncogene 22:6942-6945, 2003
26. Gemignani ML, Schlaerth AC, Bogomolniy F, et al: Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol Oncol 90: 378-381, 2003
27. Lee JW, Yoo NJ, Soung YH, et al: BRAF mutations in non-Hodgkin's lymphoma. Br J Cancer 89:1958-1960, 2003
28. Oka H, Chatani Y, Hoshino R, et al: Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res 55:4182-4187, 1995
29. Carson EB, McMahon M, Baylin SB, et al: Ret gene silencing is associated with Raf-1-induced medullary thyroid carcinoma cell differentiation. Cancer Res 55:2048-2052, 1995
30. McFarlin DR, Gould MN: Rat mammary carcinogenesis induced by in situ expression of constitutive Raf kinase activity is prevented by tethering Raf to the plasma membrane. Carcinogenesis 24:1149-11 53, 2003
31. Kerkhoff E, Fedorov LM, Siefken R, et al: Lung-targeted expression of the c-Raf-1 kinase in transgenic mice exposes a novel oncogenic character of the wild-type protein. Cell Growth Differ 11:185-190, 2000
32. Graziano SL, Pfeifer AM, Testa JR, et al: Involvement of the RAF1 locus, at band 3p25, in the 3p deletion of small-cell lung cancer. Genes Chromosomes Cancer 3:283-293, 1991
33. Patel BK, Ray S, Whiteside TL, et al: Correlation of constitutive activation of raf-1 with morphological transformation and abrogation of tyrosine phosphorylation of distinct sets of proteins in human squamous carcinoma cells. Mol Carcinog 18:1-6, 1997
34. Riva C, Lavieille JP, Reyt E, et al: Differential c-myc, c-jun, c-raf and p53 expression in squamous cell carcinoma of the head and neck: Implication in drug and radioresistance. Eur J Cancer B Oral Oncol 316:384-391, 1995
35. Ikeda S, Sumii H, Akiyama K, et al: Amplification of both c-myc and c-raf-1 oncogenes in a human osteosarcoma. Jpn J Cancer Res 80: 6-9, 1989
36. Mitsunobu F, Fukui M, Oda T, et al: A mechanism of c-raf-1 activation: Fusion of the lipocortin II amino-terminal sequence with the c-raf-1 kinase domain. Oncogene 4:437-442, 1989
37. LaRocca RV, Rosenblum M, Westermark B, et al: Patterns of proto-oncogene expression in human glioma cell lines. J Neurosci Res 24: 97-106, 1989
38. Fukui M, Yamamoto T, Kawai S, et al: Molecular cloning and characterization of an activated human c-raf-1 gene. Mol Cell Biol 7:1776-1781, 1987
39. Korshunov A, Neben K, Wrobel G, et al: Gene expression patterns in ependymomas correlate with tumor location, grade, and patient age. Am J Pathol 163:1721-1727, 2003
40. Ting LP, Jeng KS, Chou CK, et al: Expression of oncogenes in human hepatoma cell lines. Zhonghua Min Quo Wei Sheng Wu Ji Mian Yi Xue Za Zhi 21:141-150, 1988
41. Jenke HS, Deml E, Oesterle D: C-raf expression in early rat liver tumorigenesis after promotion with polychlorinated biphenyls or phenobarbital. Xenobiotica 24:569-580, 1994
42. Beer DG, Neveu MJ, Paul DL, et al: Expression of the c-raf protooncogene, gamma-glutamyltranspeptidase, and gap junction protein in rat liver neoplasms. Cancer Res 48:1610-1617, 1988
43. Berger DH, Jardines LA, Chang H, et al: Activation of Raf-1 in human pancreatic adenocarcinoma. J Surg Res 69:199-204, 1997
44. Rowinsky EK, Windle JJ, Von Hoff DD: Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. J Clin Oncol 17:3631-3652, 1999
45. Yarden Y: The EGFR family and its ligands in human cancer: Signalling mechanisms and therapeutic opportunities. Eur J Cancer 37: S3-S8, 2001 (suppl 4)
46. Boguski MS, McCormick F: Proteins regulating Ras and its relatives. Nature 366:643-654, 1993
47. English JM, Cobb MH: Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci 23:40-45, 2002
48. Kohno M, Pouyssegur J: Pharmacological inhibitors of the ERK signaling pathway: Application as anticancer drugs. Prog Cell Cycle Res 5:219-224, 2003
49. Liebmann C: Regulation of MAP kinase activity by peptide receptor signalling pathway: Paradigms of multiplicity. Cell Signal 13:777-785, 2001
50. Lewis TS, Shapiro PS, Ahn NG: Signal transduction through MAP kinase cascades. Adv Cancer Res 74:49-139, 1998
51. Kerkhoff E, Rapp UR: Cell cycle targets of Ras/Raf signalling. Oncogene 17:1457-1462, 1998
52. Chang F, Steelman LS, Shelton JG, et al: Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway. Int J Oncol 22:469-480, 2003
53. Bos JL: Ras oncogenes in human cancer: A review. Cancer Res 49:4682-4689, 1989
54. Miyakis S, Sourvinos G, Spandidos DA: Differential expression and mutation of the ras family genes in human breast cancer. Biochem Biophys Res Commun 251:609-612, 1998
55. McCormick F: Ras biology in atomic detail. Nat Struct Biol 3:653-655, 1996
56. Hancock JF, Paterson H, Marshall CJ: A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21ras to the plasma membrane. Cell 63:133-139, 1990
57. Kato K, Cox AD, Hisaka MM, et al: Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci U S A 89:6403-6407, 1992
58. Polakis P, McCormick F: Interactions between p21ras proteins and their GTPase activating proteins. Cancer Surv 12:25-42, 1992
59. Clark GJ, Cox AD, Graham SM, et al: Biological assays for Ras transformation. Methods Enzymol 255:395-412, 1995
60. Clark GJ, Der CJ: Ras Proto-Oncogene Activation in Human Malignancy. Totowa, NJ, Humana Press, 1995
61. Barbacid M: Ras genes. Annu Rev Biochem 56:779-827, 1987
62. Gibbs JB, Oliff A: The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Annu Rev Pharmacol Toxicol 37: 143-166, 1997
63. Omer CA, Anthony NJ, Buser-Doepner CA, et al: Farnesyl: Proteintransferase inhibitors as agents to inhibit tumor growth. Biofactors 6:359-366, 1997
64. Whyte DB, Kirschmeier P, Hockenberry TN, et al: K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 272:14459-14464, 1997
65. Rowell CA, Kowalczyk JJ, Lewis MD, et al: Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo. J Biol Chem 272:14093-14097, 1997
66. Prendergast GC, Oliff A: Farnesyltransferase inhibitors: Antineoplastic properties, mechanisms of action, and clinical prospects. Semin Cancer Biol 10:443-452, 2000
67. Marshall CJ: Ras effectors. Curr Opin Cell Biol 8:197-204, 1996
68. Khosravi-Far R, Campbell S, Rossman KL, et al: Increasing complexity of Ras signal transduction: Involvement of Rho family proteins. Adv Cancer Res 72:57-107, 1998
69. Smeal T, Binetruy B, Mercola DA, et al: Oncogenic and transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun on serines 63 and 73. Nature 354:494-496, 1991
70. Binetruy B, Smeal T, Karin M: Ha-Ras augments c-Jun activity and stimulates phosphorylation of its activation domain. Nature 351: 122-127, 1991
71. Pulverer BJ, Kyriakis JM, Avruch J, et al: Phosphorylation of c-jun mediated by MAP kinases. Nature 353:670-674, 1991
72. Derijard B, Raingeaud J, Barrett T, et al: Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms. Science 267:682-685, 1995
73. Bagrodia S, Derijard B, Davis RJ, et al: Cdc42 and PAK-mediated signaling leads to Jun kinase and p38 mitogen-activated protein kinase activation. J Biol Chem 270:27995-27998, 1995
74. Robinson MJ, Cobb MH: Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 9:180-186, 1997
75. Dhanasekaran N, Premkumar Reddy E: Signaling by dual specificity kinases. Oncogene 17:1447-1455, 1993
76. Schaeffer HJ, Weber MJ: Mitogen-activated protein kinases: Specific messages from ubiquitous messengers. Mol Cell Biol 19: 2435-2444, 1999
77. Zhang XF, Settleman J, Kyriakis JM, et al: Normal and oncogenic p21ras proteins bind to the amino-terminal regulatory domain of c-Raf-1. Nature 364:308-313, 1993
78. Avruch J, Khokhlatchev A, Kyriakis JM, et al: Ras activation of the Raf kinase: Tyrosine kinase recruitment of the MAP kinase cascade. Recent Prog Horm Res 56:127-155, 2001
79. Marais R, Light Y, Mason C, et al: Requirement of Ras-GTP-Raf complexes for activation of Raf-1 by protein kinase C. Science 280: 109-112, 1998
80. Stokoe D, Macdonald SG, Cadwallader K, et al: Activation of Raf as a result of recruitment to the plasma membrane. Science 264:1463-1467, 1994
81. Pritchard C, McMahon M: Raf revealed in life-or-death decisions. Nat Genet 16:214-215, 1997
82. Morrison DK, Cutler RE: The complexity of Raf-1 regulation. Curr Opin Cell Biol 9:174-179, 1997
83. Marshall CJ: Cell signaling: Raf gets it together. Nature 383:127-128, 1996
84. Leevers SJ, Paterson HF, Marshall CJ: Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane. Nature 369:411-414, 1994
85. Mason CS, Springer CJ, Cooper RG, et al: Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation. Embo J 18: 2137-2148, 1999
86. Stancato LF, Sakatsume M, David M, et al: Beta Interferon and oncostatin M activate Raf-1 and mitogen-activated protein kinase through a JAK1-dependent pathway. Mol Cell Biol 17:3833-3840, 1997
87. Farrar MA, Alberol I, Perlmutter RM: Activation of the Raf-1 kinase cascade by coumermycin-induced dimerization. Nature 383: 178-181, 1996
88. Kolch W, Heidecker G, Kochs G, et al: Protein kinase C alpha activates RAF-1 by direct phosphorylation. Nature 364:249-252, 1993
89. Yao B, Zhang Y, Delikat S, et al: Phosphorylation of Raf by ceramide-activated protein kinase. Nature 378:307-310, 1995
90. Kasid U, Suy S, Dent P, et al: Activation of Raf by ionizing radiation. Nature 382:813-816, 1996
91. Hoyos B, Imam A, Korichneva I, et al: Activation of c-Raf kinase by ultraviolet light: Regulation by retinoids. J Biol Chem 277:23949-23957, 2002
92. Tilbrook PA, Colley SM, McCarthy DJ, et al: Erythropoietin-stimulated Raf-1 tyrosine phosphorylation is associated with the tyrosine kinase Lyn in J2E erythroleukemic cells. Arch Biochem Biophys 396:128-132, 2001
93. Luo Z, Tzivion G, Belshaw PJ, et al: Oligomerization activates c-Raf-1 through a Ras-dependent mechanism. Nature 383:181-185, 1996
94. Weber CK, Slupsky JR, Kalmes HA, et al: Active Ras induces heterodimerization of cRaf and BRaf. Cancer Res 61:3595-3598, 2001
95. Hekman M, Hamm H, Villar AV, et al: Associations of B- and C-Raf with cholesterol, phosphatidylserine, and lipid second messengers: Preferential binding of Raf to artificial lipid rafts. J Biol Chem 277:24090-24102, 2002
96. Cook SJ, McCormick F: Inhibition by cAMP of Ras-dependent activation of Raf. Science 262:1069-1072, 1993
97. Hafner S, Adler HS, Mischak H, et al: Mechanism of inhibition of Raf-1 by protein kinase A. Mol Cell Biol 14:6696-6703, 1994
98. Reusch HP, Zimmermann S, Schaefer M, et al: Regulation of Raf by Akt controls growth and differentiation in vascular smooth muscle cells. J Biol Chem 276:33630-33637, 2001
99. Jansen HW, Lurz R, Bister K, et al: Homologous cell-derived oncogenes in avian carcinoma virus MH2 and murine sarcoma virus 3611. Nature 307:281-284, 1984
100. Sutrave P, Bonner TI, Rapp UR, et al: Nucleotide sequence of avian retroviral oncogene v-mil: Homologue of murine retroviral oncogene v-raf. Nature 309:85-88, 1984
101. Kan NC, Flordellis CS, Mark GE, et al: A common one gene sequence transduced by avian carcinoma virus MH2 and by murine sarcoma virus 3611. Science 223:813-816, 1984
102. Rapp UR, Goldsborough MD, Mark GE, et al: Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus. Proc Natl Acad Sci U S A 80:4218-4222, 1983
103. Calogeraki I, Barnier JV, Eychene A, et al: Genomic organization and nucleotide sequence of the coding region of the chicken c-Rmil(B-raf-1) proto-oncogene. Biochem Biophys Res Commun 193:1324-1331, 1993
104. Eychene A, Barnier JV, Apiou F, et al: Chromosomal assignment of two human B-raf(Rmil) proto-oncogene loci: B-raf-1 encoding the p94Braf/Rmil and B-raf-2, a processed pseudogene. Oncogene 7:1657-1660, 1992
105. Jaiswal RK, Weissinger E, Kolch W, et al: Nerve growth factor-mediated activation of the mitogen-activated protein (MAP) kinase cascade involves a signaling complex containing B-Raf and HSP90. J Biol Chem 271:23626-23629, 1996
106. Barnier JV, Papin C, Eychene A, et al: The mouse B-raf gene encodes multiple protein isoforms with tissue-specific expression. J Biol Chem 270:23381-23389, 1995
107. Papin C, Barnier JV, Eychene A, et al: B-raf gene encodes for multiple isoforms with Mek-1 kinase activity. C R Seances Soc Biol Fil 189:71-85, 1995
108. Nantel A, Huber M, Thomas DY: Localization of endogenous Grb10 to the mitochondria and its interaction with the mitochondrial-associated Raf-1 pool. J Biol Chem 274:35719-35724, 1999
109. Majewski M, Nieborowska-Skorska M, Salomoni P, et al: Activation of mitochondrial Raf-1 is involved in the antiapoptotic effects of Akt. Cancer Res 59:2815-2819, 1999
110. Wang HG, Rapp UR, Reed JC: Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell 87:629-638, 1996
111. Yuryev A, Ono M, Goff SA, et al: Isoform-specific localization of A-RAF in mitochondria. Mol Cell Biol 20:4870-4878, 2000
112. Morice C, Nothias F, Konig S, et al: Raf-1 and B-Raf proteins have similar regional distributions but differential subcellular localization in adult rat brain. Eur J Neurosci 11:1995-2006, 1999
113. Hagemann C, Rapp UR: Isotype-specific functions of Raf kinases. Exp Cell Res 253:34-46, 1999
114. Pritchard CA, Bolin L, Slattery R, et al: Post-natal lethality and neurological and gastrointestinal defects in mice with targeted disruption of the A-Raf protein kinase gene. Curr Biol 6:614-617, 1996
115. Houslay MD, Kolch W: Cell-type specific integration of cross-talk between extracellular signal-regulated kinase and cAMP signaling. Mol Pharmacol 58:659-668, 2000
116. Vojtek AB, Hollenberg SM, Cooper JA: Mammalian Ras interacts directly with the serine/threonine kinase Raf. Cell 74:205-214, 1993
117. Drugan JK, Khosravi-Far R, White MA, et al: Ras interaction with two distinct binding domains in Raf-1 may be required for Ras transformation. J Biol Chem 271:233-237, 1996
118. Brtva TR, Drugan JK, Ghosh S, et al: Two distinct Raf domains mediate interaction with Ras. J Biol Chem 270:9809-9812, 1995
119. Guan KL, Figueroa C, Brtva TR, et al: Negative regulation of the serine/threonine kinase B-Raf by Akt. J Biol Chem 275:27354-27359, 2000
120. Morrison DK, Heidecker G, Rapp UR, et al: Identification of the major phosphorylation sites of the Raf-1 kinase. J Biol Chem 268: 17309-17316, 1993
121. Zimmermann S, Moelling K: Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 286:1741-1744, 1999
122. Mikula M, Schreiber M, Husak Z, et al: Embryonic lethality and fetal liver apoptosis in mice lacking the c-raf-1 gene. Embo J 20:1952-1962, 2001
123. Wu X, Noh SJ, Zhou G, et al: Selective activation of MEK1 but not MEK2 by A-Raf from epidermal growth factor-stimulated Hela cells. J Biol Chem 271:3265-3271, 1996
124. Marais R, Light Y, Paterson HF, et al: Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases. J Biol Chem 272:4378-4383, 1997
125. Pritchard CA, Samuels ML, Bosch E, et al: Conditionally oncogenic forms of the A-Raf and B-Raf protein kinases display different biological and biochemical properties in NIH 3T3 cells. Mol Cell Biol 15:6430-6442, 1995
126. Kubicek M, Pacher M, Abraham D, et al: Dephosphorylation of Ser-259 regulates Raf-1 membrane association. J Biol Chem 277:7913-7919, 2002
127. Chuang E, Barnard D, Hettich L, et al: Critical binding and regulatory interactions between Ras and Raf occur through a small, stable N-terminal domain of Raf and specific Ras effector residues. Mol Cell Biol 14:5318-5325, 1994
128. Voice JK, Klemke RL, Le A, et al: Four human ras homologs differ in their abilities to activate Raf-1, induce transformation, and stimulate cell motility. J Biol Chem 274:17164-17170, 1999
129. Okada T, Hu CD, Jin TG, et al: The strength of interaction at the Raf cysteine-rich domain is a critical determinant of response of Raf to Ras family small GTPases. Mol Cell Biol 19:6057-6064, 1999
130. Yamamori B, Kuroda S, Shimizu K, et al: Purification of a Ras-dependent mitogen-activated protein kinase kinase kinase from bovine brain cytosol and its identification as a complex of B-Raf and 14-3-3 proteins. J Biol Chem 270:11723-11726, 1995
131. Vossler MR, Yao H, York RD, et al: CAMP activates MAP kinase and Elk-1 through a B-Raf- and Rap1-dependent pathway. Cell 89:73-82, 1997
132. York RD, Yao H, Dillon T, et al: Rap1 mediates sustained MAP kinase activation induced by nerve growth factor. Nature 392:622-626, 1998
133. Bos JL, de Rooij J, Reedquist KA: Rap1 signalling: Adhering to new models. Nat Rev Mol Cell Biol 2:369-377, 2001
134. Chaudhary A, King WG, Mattaliano MD, et al: Phosphatidylinositol 3-kinase regulates Raf1 through Pak phosphorylation of serine 338. Curr Biol 10:551-554, 2000
135. Diaz B, Barnard D, Filson A, et al: Phosphorylation of Raf-1 serine 338-serine 339 is an essential regulatory event for Ras-dependent activation and biological signaling. Mol Cell Biol 17:4509-4516, 1997
136. King AJ, Sun H, Diaz B, et al: The protein kinase Pak3 positively regulates Raf-1 activity through phosphorylation of serine 338. Nature 396:180-183, 1998
137. Dhillon AS, Meikle S, Yazici Z, et al: Regulation of Raf-1 activation and signalling by dephosphorylation. Embo J 21:64-71, 2002
138. Zhang BH, Tang ED, Zhu T, et al: Serum- and glucocorticoid-inducible kinase SGK phosphorylates and negatively regulates B-Raf. J Biol Chem 276:31620-31626, 2001
139. Dhillon AS, Meikle S, Peyssonnaux C, et al: A Raf-1 mutant that dissociates MEK/extracellular signal-regulated kinase activation from malignant transformation and differentiation but not proliferation. Mol Cell Biol 23:1983-1993, 2003
140. Chong H, Lee J, Guan KL: Positive and negative regulation of Raf kinase activity and function by phosphorylation. Embo J 20:3716-3727, 2001
141. Fabian JR, Daar IO, Morrison DK: Critical tyrosine residues regulate the enzymatic and biological activity of Raf-1 kinase. Mol Cell Biol 13:7170-7179, 1993
142. Sun H, King AJ, Diaz HB, et al: Regulation of the protein kinase Raf-1 by oncogenic Ras through phosphatidylinositol 3-kinase, Cdc42/ Rac and Pak. Curr Biol 10:281-284, 2000
143. Campbell S, Otis M, Cote M, et al: Connection between integrins and cell activation in rat adrenal glomerulosa cells: A role for Arg-Gly-Asp peptide in the activation of the p42/ p44(mapk) pathway and intracellular calcium. Endocrinology 144:1486-1495, 2003
144. Zhang BH, Guan KL: Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601. Embo J 19:5429-5439, 2000
145. Wojnowski L, Stancato LF, Larner AC, et al: Overlapping and specific functions of Braf and Craf-1 proto-oncogenes during mouse embryogenesis. Mech Dev 91:97-104, 2000
146. Dent P, Haser W, Haystead TA, et al: Activation of mitogen-activated protein kinase kinase by v-Raf in NIH 3T3 cells and in vitro. Science 257:1404-1407, 1992
147. Catling AD, Reuter CW, Cox ME, et al: Partial purification of a mitogen-activated protein kinase kinase activator from bovine brain: Identification as B-Raf or a B-Raf-associated activity. J Biol Chem 269:30014-30021, 1994
148. Catling AD, Schaeffer HJ, Reuter CW, et al: A proline-rich sequence unique to MEK1 and MEK2 is required for raf binding and regulates MEK function. Mol Cell Biol 15:5214-5225, 1995
149. Howe LR, Leevers SJ, Gomez N, et al: Activation of the MAP kinase pathway by the protein kinase raf. Cell 71:335-342, 1992
150. Kyriakis JM, App H, Zhang XF, et al: Raf-1 activates MAP kinase-kinase. Nature 358:417-421, 1992
151. Jaiswal RK, Moodie SA, Wolfman A, et al: The mitogen-activated protein kinase cascade is activated by B-Raf in response to nerve growth factor through interaction with p21ras. Mol Cell Biol 14:6944-6953, 1994
152. Yan M, Templeton DJ: Identification of 2 serine residues of MEK-1 that are differentially phosphorylated during activation by raf and MEK kinase. J Biol Chem 269:19067-19073, 1994
153. Reuter CW, Catling AD, Jelinek T, et al: Biochemical analysis of MEK activation in NIH3T3 fibroblasts: Identification of B-Raf and other activators. J Biol Chem 270:7644-7655, 1995
154. Kolch W: Meaningful relationships: The regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J 351:289-305, 2000
155. Baumann B, Weber CK, Troppmair J, et al: Raf induces NF-kappaB by membrane shuttle kinase MEKK1, a signaling pathway critical for transformation. Proc Natl Acad Sci U S A 97: 4615-4620, 2000
156. Wang S, Ghosh RN, Chellappan SP: Raf-1 physically interacts with Rb and regulates its function: A link between mitogenic signaling and cell cycle regulation. Mol Cell Biol 18:7487-7498, 1998
157. Wang HG, Miyashita T, Takayama S, et al: Apoptosis regulation by interaction of Bcl-2 protein and Raf-1 kinase. Oncogene 9:2751-2756, 1994
158. Papin C, Denouel A, Calothy G, et al: Identification of signalling proteins interacting with B-Raf in the yeast two-hybrid system. Oncogene 12:2213-2221, 1996
159. Ahn NG, Seger R, Bratlien RL, et al: Multiple components in an epidermal growth factor-stimulated protein kinase cascade: In vitro activation of a myelin basic protein/microtubule-associated protein 2 kinase. J Biol Chem 266: 4220-4227, 1991
160. Crews CM, Alessandrini A, Erikson RL: The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product. Science 258:478-480, 1992
161. Morrison DK: KSR: A MAPK scaffold of the Ras pathway? J Cell Sci 114:1609-1612, 2001
162. Michaud NR, Therrien M, Cacace A, et al: KSR stimulates Raf-1 activity in a kinase-independent manner. Proc Natl Acad Sci U S A 94:12792-12796, 1997
163. Galaktionov K, Jessus C, Beach D: Raf1 interaction with Cdc25 phosphatase ties mitogenic signal transduction to cell cycle activation. Genes Dev 9:1046-1058, 1995
164. Jinno S, Suto K, Nagata A, et al: Cdc25A is a novel phosphatase functioning early in the cell cycle. Embo J 13:1549-1556, 1994
165. Janosch P, Kieser A, Eulitz M, et al: The Raf-1 kinase associates with vimentin kinases and regulates the structure of vimentin filaments. FASEB J 14:2008-2021, 2000
166. Li S, Sedivy JM: Raf-1 protein kinase activates the NF-kappa B transcription factor by dissociating the cytoplasmic NF-kappa B-I kappa B complex. Proc Natl Acad Sci U S A 90:9247-9251, 1993
167. Peruzzi F, Prisco M, Dews M, et al: Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis. Mol Cell Biol 19:7203-7215, 1999
168. Patriotis C, Russeva MG, Lin JH, et al: Tpl-2 induces apoptosis by promoting the assembly of protein complexes that contain caspase-9, the adapter protein Tvl-1, and procaspase-3. J Cell Physiol 187:176-187, 2001
169. Chen J, Fujii K, Zhang L, et al: Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism. Proc Natl Acad Sci U S A 98:7783-7788, 2001
170. Jamal S, Ziff EB: Raf phosphorylates p53 in vitro and potentiates p53-dependent transcriptional transactivation in vivo. Oncogene 10:2095-2101, 1995
171. Nilsson I, Hoffmann I: Cell cycle regulation by the Cdc25 phosphatase family. Prog Cell Cycle Res 4:107-114, 2000
172. Cornwell MM, Smith DE: A signal transduction pathway for activation of the mdr1 promoter involves the proto-oncogene c-raf kinase. J Biol Chem 268:15347-15350, 1993
173. Harris P, Morton CC, Guglielmi P, et al: Mapping by chromosome sorting of several gene probes, including c-myc, to the derivative chromosomes of a 3;8 translocation associated with familial renal cancer. Cytometry 7:589-594, 1986
174. Miyamoto K, Tomita N, Ishii A, et al: Specific abnormalities of chromosome 14 in patients with acute type of adult T-cell leukemia/ lymphoma. Int J Cancer 40:461-468, 1987
175. Nagao M, Ishikawa F, Tahira T, et al: Activation of rat and human c-raf(-1) by rearrangement. Princess Takamatsu Symp 17:75-84, 1986
176. Huser M, Luckett J, Chiloeches A, et al: MEK kinase activity is not necessary for Raf-1 function. Embo J 20:1940-1951, 2001
177. Niehof M, Radziwill G, Klauser S, et al: A small peptide derived from the aminoterminus of c-Raf-1 inhibits c-Raf-1/Ras binding. Biochem Biophys Res Commun 206:46-50, 1995
178. Metzelaar-Blok JA, Jager MJ, Moghaddam PH, et al: Frequent loss of heterozygosity on chromoter mosome 6p in uveal melanoma. Hum Immunol 60:962-969, 1999
179. Cohen Y, Goldenberg-Cohen N, Parrella P, et al: Lack of BRAF mutation in primary uveal melanoma. Invest Ophthalmol Vis Sci 44:2876-2878, 2003
180. Pollock PM, Harper UL, Hansen KS, et al: High frequency of BRAF mutations in nevi. Nat Genet 33:19-20, 2003
181. Takayama T, Ohi M, Hayashi T, et al: Analysis of K-ras, APC, and beta-catenin in aberrant crypt foci in sporadic adenoma, cancer, and familial adenomatous polyposis. Gastroenterology 121:599-611, 2001
182. Yamashita N, Minamoto T, Ochiai A, et al: Frequent and characteristic K-ras activation in aberrant crypt foci of colon: Is there preference among K-ras mutants for malignant progression? Cancer 75:1527-1533, 1995
183. Busca R, Abbe P, Mantoux F, et al: Ras mediates the cAMP-dependent activation of extracellular signal-regulated kinases (ERKs) in melanocytes. Embo J 19:2900-2910, 2000
184. Iacovelli L, Capobianco L, Salvatore L, et al: Thyrotropin activates mitogen-activated protein kinase pathway in FRTL-5 by a cAMP-dependent protein kinase A-independent mechanism. Mol Pharmacol 60:924-933, 2001
185. Manning G, Whyte DB, Martinez R, et al: The protein kinase complement of the human genome. Science 298:1912-1934, 2002
186. Stanton VP Jr, Cooper GM: Activation of human raf transforming genes by deletion of normal amino-terminal coding sequences. Mol Cell Biol 7:1171-1179, 1987
187. Kasid U, Pfeifer A, Weichselbaum RR, et al: The raf oncogene is associated with a radiation-resistant human laryngeal cancer. Science 237:1039-1041, 1987
188. Yu X, Guo ZS, Marcu MG, et al: Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst 94:504-513, 2002
189. Carter G, Lemoine NR: Antisense technology for cancer therapy: Does it make sense? Br J Cancer 67:869-876, 1993
190. Stephens AC, Rivers RP: Antisense oligonucleotide therapy in cancer. Curr Opin Mol Ther 5:118-122, 2003
191. Monia BP, Sasmor H, Johnston JF, et al: Sequence-specific antitumor activity of a phos-phorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo. Proc Natl Acad Sci U S A 93:15481-15484, 1996
192. Monia BP, Johnston JF, Geiger T, et al: Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat Med 2:668-675, 1996
193. Gokhale PC, McRae D, Monia BP, et al: Antisense raf oligodeoxyribonucleotide is a radiosensitizer in vivo. Antisense Nucleic Acid Drug Dev 9:191-201, 1999
194. Henry SP, Monteith D, Bennett F, et al: Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-alpha and C-raf kinase. Anticancer Drug Des 12:409-420, 1997
195. Phillips JA, Craig SJ, Bayley D, et al: Pharmacokinetics, metabolism, and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration. Biochem Pharmacol 54:657-668, 1997
196. Geary RS, Leeds JM, Fitchett J, et al: Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression. Drug Metab Dispos 25:1272-1281, 1997
197. Cunningham CC, Holmlund JT, Schiller JH, et al: A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res 6:1626-1631, 2000
198. Stevenson JP, Yao KS, Gallagher M, et al: Phase I clinical/ pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A). J Clin Oncol 17:2227-2236, 1999
199. Rudin CM, Holmlund J, Fleming GF, et al: Phase I trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer. Clin Cancer Res 7:1214-1220, 2001
200. Tolcher AW, Reyno L, Venner PM, et al: A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer. Clin Cancer Res 8:2530-2535, 2002
201. Cripps MC, Figueredo AT, Oza AM, et al: Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal
202. Oza AM, Elit L, Swenerton K, et al: Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: An NCIC Clinical Trials Group study (NCIC IND. 116). Gynecol Oncol 89:129-133, 2003
203. Coudert B, Anthoney A, Fiedler W, et al: Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer: A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report. Eur J Cancer 37: 2194-2198, 2001
204. Bonner TI, Kerby SB, Sutrave P, et al: Structure and biological activity of human ho-mologs of the raf/mil oncogene. Mol Cell Biol 5:1400-1407, 1985
205. Wan PT, Garnett MJ, Roe SM, et al: Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116:855-867, 2004
206. Wilhelm S, Chien DS: BAY 43-9006: Preclinical data. Curr Pharm Des 8:2255-2257, 2002
207. Choi YJ, Fanidi A, White S, et al: The novel inhibitor BAY 43-9006 blocks signaling and proliferation in b-Raf mutant and wild type melanoma and colorectal tumor cell lines. Presented at Am Assoc Cancer Res 94th Annual Meeting, Washington, DC, July11-14, 2003
208. Wilhelm S, Carter C, Tang L, et al: BAY 43-9006 exhibits broad spectrum anti-tumor activity and targets raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Presented at the 2003 AACR-NCI-EORTC International Conference for Molecular Targets and Cancer Therapeutics, Boston, MA, November 17-21, 2003
209. Carter C, Deuringer P, etal: Investigators Brochure BAY 43-9006/ Raf Kinase Inhibitor Version No. 4.1. West Haven, CT, Bayer Pharmaceuticals Corporation, 2003
210. Wilhelm SM, Carter C, Tang LY, et al: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099-7109, 2004
211. Alavi A, Hood JD, Frausto R, et al: Role of Raf in vascular protection from distinct apoptotic stimuli. Science 301:94-96, 2003
212. Vincent P, Zhang X, Chen CM, et al: Preclinical chemotherapy with the Raf kinase inhibitor BAY 43-9006 in combination with gefitinib, vinorelbine, gemcitabine and doxorubicin. Presented at Am Assoc Cancer Res 94th Annual Meeting, Washington, DC, July11-14, 2003
213. Lyons JF, Wilhelm S, Hibner B, et al: Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 8:219-225, 2001
214. Activity of the Raf kinase inhibitor BAY 43-9006 in patients with advanced solid tumors. Clin Colorectal Cancer 3:16-18, 2003
215. Strumberg D, Voliotis D, Moeller JG, et al: Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors. Int J Clin Pharmacol Ther 40:580-581, 2002
216. Hilger RA, Kredke S, Hedley D, et al: Inhibition of ERK phosphorylation in patients treated with the Raf kinase inhibitor BAY 43-9006. Eur J Cancer 38:S52-S53, 2002
217. Kopec JA, Abrahamowicz M, Esdaile JM: Randomized discontinuation trials: Utility and efficiency. J Clin Epidemiol 46:959-971, 1993
218. Ratain MJ, Flaherty K, Stadler WM, et al: Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT). J Clin Oncol 22:381s, 2004 (suppl; abstr 4501)
219. Ratain MJ, Eisen T, Stadler WM: Final findings from a Phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol 23:388s, 2005 (suppl; abstr 4544)
220. Escudier B, Szczylik C, Eisen T, et al: Randomized phase III trial of the Rafkinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 23:380s, 2005 (suppl; abstr LBA4510)
221. Ahmad T, Marias R, Pyle L, et al: BAY 43-9006 in patients with advanced melanoma: The Royal Marsden experience. J Clin Oncol 22:708s, 2004 (suppl; abstr 7506)
222. Flaherty KT, Brose M, Schuchter L, et al: Phase I/II trial of BAY 43-9006, carboplatin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma. J Clin Oncol 22: 708s, 2004 (suppl; abstr 7507)
223. Siu LL, Takimoto CH, Awada A, et al: A phase I/II trial of BAY 43-9006 and gemcitabine in advanced solid tumors and in advanced pancreatic cancer. J Clin Oncol 22:209s, 2004 (suppl; abstr 3059)
224. Richly H, Kupsch P, Passage K, et al: A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors. Int J Clin Pharmacol Ther 41:620-621, 2003
225. Heim M, Sharifi M, Hilger RA, et al: Antitumor effect and potentiation or reduction in cytotoxic drug activity in human colon carcinoma cells by the Raf kinase inhibitor (RKI) BAY 43-9006. Int J Clin Pharmacol Ther 41:616-617, 2003
226. Mross K, Steinbild S, Baas F, et al: Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors. Int J Clin Pharmacol Ther 41:618-619, 2003
227. Kupsch P, Passarge K, Richly H, et al: Results of a phase I trial of BAY 43-9006 in combination with oxaliplatin in patients with refractory solid tumors. J Clin Oncol 22:209s, 2004 (suppl; abstr 3056)
228. Heimbrook HE, Huber SM, Stirdivant D, et al: Identification of potent selective kinase inhibitors of Raf. Presented at Am Assoc Cancer Res 89th Annual Meeting, New Orleans, LA, March 28-April 1, 1998 (abstr 3793)
229. Shelton JG, Moye PW, Steelman LS, et al: Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation. Leukemia 17:1765-1782, 2003
230. Lackey K, Cory M, Davis R, et al: The discovery of potent cRaf1 kinase inhibitors. Bioorg Med Chem Lett 10:223-226, 2000
231. Wood E, Crosby RM, Dickerson S, et al: A prodrug approach to the design of cRaf1 kinase inhibitors with improved cellular activity. Anticancer Drug Des 16:1-6, 2001
232. Hall-Jackson CA, Goedert M, Hedge P, et al: Effect of SB 203580 on the activity of c-Raf in vitro and in vivo. Oncogene 18:2047-2054, 1999
233. Maloney A, Workman P: HSP90 as a new therapeutic target for cancer therapy: The story unfolds. Expert Opin Biol Ther 2:3-24, 2002
234. Sausville EA, Tomaszewski JE, Ivy P: Clinical development of 17-allylamino, 17-demethoxy-geldanamycin. Curr Cancer Drug Targets 3:377-383, 2003
235. Ikuina Y, Amishiro N, Miyata M, et al: Synthesis and antitumor activity of novel O-carbamoylmethyloxime derivatives of radicicol. J Med Chem 46:2534-2541, 2003
236. Hood JD, Bednarski M, Frausto R, et al: Tumor regression by targeted gene delivery to the neovasculature. Science 296:2404-2407, 2002